Immunophotonics Revenue and Competitors
Estimated Revenue & Valuation
- Immunophotonics's estimated annual revenue is currently $1.8M per year.
- Immunophotonics's estimated revenue per employee is $100,500
Employee Data
- Immunophotonics has 18 Employees.
- Immunophotonics grew their employee count by 64% last year.
Immunophotonics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2233.5M | 6945 | 16% | N/A | N/A |
#2 | $11.5M | 57 | 2% | N/A | N/A |
#3 | $13.7M | 68 | -8% | N/A | N/A |
#4 | $11.5M | 57 | 10% | N/A | N/A |
#5 | $42M | 209 | 4% | N/A | N/A |
#6 | $1.8M | 18 | 64% | N/A | N/A |
#7 | $6.8M | 34 | -13% | N/A | N/A |
#8 | $9.2M | 46 | 2% | N/A | N/A |
#9 | $1099.9M | 3420 | 0% | $97M | N/A |
#10 | $18.5M | 92 | 0% | N/A | N/A |
What Is Immunophotonics?
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.
keywords:N/AN/A
Total Funding
18
Number of Employees
$1.8M
Revenue (est)
64%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 18 | -14% | N/A |
#2 | $2.3M | 18 | -31% | N/A |
#3 | $2.9M | 18 | 29% | N/A |
#4 | $1.6M | 18 | -18% | N/A |
#5 | $2.9M | 18 | -49% | N/A |